StreetInsider.com News Articles

Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Full Fiscal Year 2025 Topline Financial Results

Wed, 07 Jan 2026 08:30:00 -0500

SAN CLEMENTE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced preliminary financial results for the fourth quarter and full fiscal year, for the period ended December 31, 2025.

Preliminary Financial Results

Fourth quarter 2025 revenue is expected to total between $28.6 million and $28.9 million, as compared to approximately $18.3 million in the same period last year, reflecting an increase of approximately 57% compared to the same period last year.
Full fiscal 2025 revenue is

Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Full Fiscal Year 2025 Topline Financial Results

Wed, 07 Jan 2026 08:30:00 -0500

Preliminary Financial Results

Fourth quarter 2025 revenue is expected to total between $28.6 million and $28.9 million, as compared to approximately $18.3 million in the same period last year, reflecting an increase of approximately 57% compared to the same period last year.
Full fiscal 2025 revenue is

Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Full Fiscal Year 2025 Topline Financial Results

Wed, 07 Jan 2026 08:30:00 -0500

Preliminary Financial Results

Fourth quarter 2025 revenue is expected to total between $28.6 million and $28.9 million, as compared to approximately $18.3 million in the same period last year, reflecting an increase of approximately 57% compared to the same period last year.
Full fiscal 2025 revenue is

Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Full Fiscal Year 2025 Topline Financial Results

Wed, 07 Jan 2026 08:30:00 -0500

Preliminary Financial Results

Fourth quarter 2025 revenue is expected to total between $28.6 million and $28.9 million, as compared to approximately $18.3 million in the same period last year, reflecting an increase of approximately 57% compared to the same period last year.
Full fiscal 2025 revenue is

Sofwave Medical Reports Third Quarter 2025 Financial Results and Business Highlights

Tue, 04 Nov 2025 08:30:00 -0500

— Record quarterly revenue in third quarter of $21.1M, +56% year-over-year growth; IFRS gross margin of 73.7%

— Third quarter pulse recurring revenue of $8.3M, +55% year-over-year growth

— First nine months revenue of $58.7M, +42% year-over-year growth; IFRS gross margin of 75.1%

— First nine months IFRS and non-IFRS net income of $1.4M and $3.2M, respectively, versus a net loss of $3.8M and $2.1M, respectively, in the same year ago period

— Approximately 667,00 pulse treatments administered since commercialization

Sofwave Medical Reports Third Quarter 2025 Financial Results and Business Highlights

Tue, 04 Nov 2025 08:30:00 -0500

— Record quarterly revenue in third quarter of $21.1M, +56% year-over-year growth; IFRS gross margin of 73.7%

— Third quarter pulse recurring revenue of $8.3M, +55% year-over-year growth

— First nine months revenue of $58.7M, +42% year-over-year growth; IFRS gross margin of 75.1%

— First nine months IFRS and non-IFRS net income of $1.4M and $3.2M, respectively, versus a net loss of $3.8M and $2.1M, respectively, in the same year ago period

— Approximately 667,00 pulse treatments administered since commercialization

Sofwave Medical Reports Third Quarter 2025 Financial Results and Business Highlights

Tue, 04 Nov 2025 08:30:00 -0500

— Record quarterly revenue in third quarter of $21.1M, +56% year-over-year growth; IFRS gross margin of 73.7%

— Third quarter pulse recurring revenue of $8.3M, +55% year-over-year growth

— First nine months revenue of $58.7M, +42% year-over-year growth; IFRS gross margin of 75.1%

— First nine months IFRS and non-IFRS net income of $1.4M and $3.2M, respectively, versus a net loss of $3.8M and $2.1M, respectively, in the same year ago period

— Approximately 667,00 pulse treatments administered since commercialization

Sofwave Medical Reports Third Quarter 2025 Financial Results and Business Highlights

Tue, 04 Nov 2025 08:30:00 -0500

— Record quarterly revenue in third quarter of $21.1M, +56% year-over-year growth; IFRS gross margin of 73.7%

— Third quarter pulse recurring revenue of $8.3M, +55% year-over-year growth

— First nine months revenue of $58.7M, +42% year-over-year growth; IFRS gross margin of 75.1%

— First nine months IFRS and non-IFRS net income of $1.4M and $3.2M, respectively, versus a net loss of $3.8M and $2.1M, respectively, in the same year ago period

— Approximately 667,00 pulse treatments administered since commercialization

Sofwave to Participate in Upcoming November Investor Conferences

Wed, 29 Oct 2025 08:00:00 -0500

SAN CLEMENTE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that management will participate in the following investor conferences:

Stifel 2025 Healthcare Conference
Presentation Format: Corporate overview
Presentation Date: Wednesday, November 12, 2025
Presentation Time: 10:40 a.m. ET
Webcast: Click Here

Jefferies London Healthcare Conference
Presentation Format: Corporate overview
Presentation Date: Wednesday, November 19, 2025
Presentation Time: 9:30 a.m. GMT
Webcast: Click Here

Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Presentation Format: Corporate overview
Presentation

Sofwave to Participate in Upcoming November Investor Conferences

Wed, 29 Oct 2025 08:00:00 -0500

Stifel 2025 Healthcare Conference
Presentation Format: Corporate overview
Presentation Date: Wednesday, November 12, 2025
Presentation Time: 10:40 a.m. ET
Webcast: Click Here

Jefferies London Healthcare Conference
Presentation Format: Corporate overview
Presentation Date: Wednesday, November 19, 2025
Presentation Time: 9:30 a.m. GMT
Webcast: Click Here

Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Presentation Format: Corporate overview
Presentation

Sofwave to Participate in Upcoming November Investor Conferences

Wed, 29 Oct 2025 08:00:00 -0500

Stifel 2025 Healthcare Conference
Presentation Format: Corporate overview
Presentation Date: Wednesday, November 12, 2025
Presentation Time: 10:40 a.m. ET
Webcast: Click Here

Jefferies London Healthcare Conference
Presentation Format: Corporate overview
Presentation Date: Wednesday, November 19, 2025
Presentation Time: 9:30 a.m. GMT
Webcast: Click Here

Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Presentation Format: Corporate overview
Presentation

Sofwave to Participate in Upcoming November Investor Conferences

Wed, 29 Oct 2025 08:00:00 -0500

Stifel 2025 Healthcare Conference
Presentation Format: Corporate overview
Presentation Date: Wednesday, November 12, 2025
Presentation Time: 10:40 a.m. ET
Webcast: Click Here

Jefferies London Healthcare Conference
Presentation Format: Corporate overview
Presentation Date: Wednesday, November 19, 2025
Presentation Time: 9:30 a.m. GMT
Webcast: Click Here

Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Presentation Format: Corporate overview
Presentation

Sofwave to Participate in the Jefferies Virtual Private MedTech Summit

Mon, 29 Sep 2025 08:30:00 -0500

SAN CLEMENTE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the Jefferies Virtual Private MedTech Summit on October 1st, 2025.

About Sofwave Medical
Sofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology, is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax

Sofwave to Participate in the Jefferies Virtual Private MedTech Summit

Mon, 29 Sep 2025 08:30:00 -0500

Sofwave to Participate in the Jefferies Virtual Private MedTech Summit

Mon, 29 Sep 2025 08:30:00 -0500

Sofwave to Participate in the Jefferies Virtual Private MedTech Summit

Mon, 29 Sep 2025 08:30:00 -0500

Sofwave Receives FDA, Pre-market Clearance for Pure Impact VIPTM Standalone EMS Device For Comprehensive Multi-Body Area Muscle Strengthening and Firming

Thu, 04 Sep 2025 08:30:00 -0500

The Pure Impact VIP™ standalone device represents a major extension of the Pure Impact™ product line and introduces an all-in-one independent unit
Standalone device is launched with an enhanced Pure Impact™ feature set which provides comprehensive muscle strengthening programs that focus on multiple body areas including the: abdomen, arms, thighs, and buttocks and enables simultaneous treatment of 6 muscle groups
In the recent McKinsey Life Sciences Practices report, 63% of GLP-1 patients seeking aesthetic services are new to the market and skin laxity was noted as the primary aesthetic patient concern